Bupropion for the treatment of tobacco dependence: Guidelines for balancing risks and benefits

CNS Drugs

Volumn 17, Issue 2, 2003, Pages 71-83

  Hays, J Taylor ^a   Ebbert, Jon O ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; NICOTINE;

ABSTINENCE; ANXIETY; BEHAVIOR THERAPY; BRAIN REGION; CIGARETTE SMOKING; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEADACHE; HUMAN; INSOMNIA; LIMBIC CORTEX; LONG TERM CARE; MENTAL DISEASE; MORBIDITY; MORTALITY; NAUSEA; NICOTINE REPLACEMENT THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RELAPSE; REVIEW; RISK FACTOR; SMOKING CESSATION; SUSTAINED RELEASE PREPARATION; TOBACCO DEPENDENCE; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; HUMANS; RISK ASSESSMENT; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 0037273008     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317020-00001     Document Type: Review

References (49)

1. Corrao MA, Guidon GE, Sharma N, et al. Tobacco control country profiles. Atlanta (GA): American Cancer Society, 2000
2. Peto R, Lopez A, Boreham J, et al. Mortality from smoking in developed countries 1950-2000, in indirect estimates from National Vital Statistics. New York: Oxford University Press, 1994
3. Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994; 271: 1940-7
4. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation (Cochrane Review). Cochrane Tobacco Addiction Group module of The Cochrane Database of Systemic Reviews. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Oxford Update Software, 2002
5. Breslau N, Kilbey MM, Andreski P. Nicotine dependence, major depression, and anxiety disorder in young adults. Arch Gen Psychiatry 1991; 48: 1069-74
6. Tsoh JY, Humfleet GL, Munoz RF, et al. Development of major depression after treatment for smoking cessation. Am J Psychiatry 2000; 157: 368-74
7. Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry 1993; 11 (1): 2-14
8. Watkins SS, Koob G, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2000; 2 (1): 19-37
9. Medicines Control Agency (MCA). Zyban (bupropion hydrochloride): safety update [online]. Available from URL: http://www.mca.gov.uk/ourwork/monitorsafequalmed/safetymessages/zyban.pdf [Accessed 2002 Jan 17]
10. Canadian Medical Association Journal. Bupropion (Zyban, Wellbutrin SR): reports of death, seizures, serum sickness [online]. Available from URL: http://www.cma.ca/cmaj/FDA-Advisory/Bupropion-12-12.htm [Accessed 2002 Jul 26]
11. Center for Adverse Reactions Monitoring (CARM). Bupropion (Zyban) for second-line treatment only [online]. Available from URL: http://www.medsafe.govt.nz/Profs/PUarticles/zyban.htm [Accessed 2002 Jul 25]
12. Adverse Drug Reactions Advisory Committee (ADRAC). Update on bupropion (Zyban SR)-31 August 2001 [online]. Available from URL: http://www.health.gov.au/tga/docs/html/zyban.htm [Accessed 2002 Jul 30]
13. Shiffman S, Johnston J, Khayrallah M, et al. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 2000; 148: 33-40
14. Slemmer JE, Martin B, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295: 321-7
15. Benowitz N, Wilson Peng M. Non-nicotine pharmacotherapy for smoking cessation. CNS Drugs 2000; 13 (4): 265-85
16. Hayford KE, Patten C, Rummans TA, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999; 174: 173-8
17. Hurt RD, Sachs D, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-202
18. Jorenby DE, Leischow S, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-91
19. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357 (9268): 1571-5
20. Gonzales DH, Nides M, Ferry LH, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 2001; 69 (6): 438-44
21. Dale LC, Glover ED, Sachs DP, et al. Bupropion for smoking cessation: predictors of successful outcome. Chest 2001; 119: 1357-64
22. Hays JT, Hurt R, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med 2001; 135 (6): 423-33
23. Johnston JA, Fiedler-Kelly J, Glover ED, et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 2001; 3: 131-40
24. Hughes JR, Hatsukami DK, Mitchell JE, et al. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143: 993-7
25. de Leon J, Dadvand M, Canuso C, et al. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 1995; 152: 453-5
26. Breslau N. Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet 1995; 25: 95-101
27. Leonard S, Adler L, Benhammou K, et al. Smoking and mental illness. Pharmacol Biochem Behav 2001; 70: 561-70
28. Weiner E, Ball M, Summerfelt A, et al. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 2001; 158 (4): 635-7
29. Evins AE, Mays V, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001; 3: 397-403
30. Hertzberg MA, Moore S, Feldman ME, et al. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. J Clin Psychopharmocol 2001; 21 (1): 94-8
31. Chengappa KNR, Kambhampati RK, Perkins K, et al. Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. J Clin Psychiatry 2001; 62: 503-8
32. Prochazka AV, Weaver M, Keller RT, et al. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158: 2035-9
33. Hall SM, Reus V, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55: 683-90
34. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence, in clinical practice guideline: US Department of Health and Human Services. Rockville (MD): Public Health Service, 2000 Jun
35. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000; 55 (12): 987-99
36. Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997; 37: 737-43
37. Preskorn SH, Othmer S. Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants. Pharmacotherapy 1984; 4: 20-34
38. Johnston JA, Lineberry C, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52: 450-6
39. Zyban prescribing information. Research Triangle Park (NC): Glaxo Smith Kline, 2002 Apr
40. Peloso PM, Baillie C. Serum sickness-like reaction with bupropion [letter]. JAMA 1999; 282 (19): 1817
41. Kiev A, Masco H, Wenger TL, et al. The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. Ann Clin Psychiatry 1994; 6 (2): 107-15
42. Roose SP, Dalack G, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991; 148 (4): 512-6
43. Roose SP, Glassman A, Giardina EG, et al. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol 1987; 7: 247-51
44. Bupropion pregnancy registry interim report. Research Triangle Park (NC): Glaxo Wellcome, 1999 May
45. Annegers JF, Hauser W, Coan SP, et al. A population-based study of seizures after traumatic brain injuries. N Engl J Med 1998; 338 (1): 20-4
46. Gonzales D, Bjornson W, Durcan MJ, et al. Effects of gender on abstinence and relapse in smokers treated with bupropion SR. Am J Prev Med 2002; 22: 234-9
47. Jamerson BD, Nides M, Jorenby DE, et al. Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. Clin Ther 2001; 23 (5): 744-52
48. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and mania. In: Hardman JG, Limird LE, Molinoff PB, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:431-60
49. Nielsen K, Fiore M. Cost benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation. Prev Med 2000; 30: 209-16